Loading clinical trials...

Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer. | Clinical Trials | Clareo Health

UNKNOWNPHASE2

Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.

NCT00043446•Tularik

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Histologically or cytologically confirmed diagnosis of ovarian cancer
•Subjects must have received 1-2 regimens of prior chemotherapy (with one containing paclitaxel)
•At least 18 years of age
•Bidimensionally measurable disease amenable to CT scanning. At least one lesion must be least 1 X 1 cm in size.
•Karnofsky performance status of at least 70%
•Estimated life expectancy of at least 12 weeks
•Females of childbearing potential must have a negative pregnancy test and agree to use an effective contraceptive
•Subject must be able to comply with study procedures and follow-up examinations.
•Signed written informed consent
•Lab Values (obtained ≤ 7 days prior to study enrollment):
+8 more criteria

Exclusion Criteria

•Severe, concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment
•NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of \<50%, or acute anginal symptoms
•Patients who have received any investigational agent within 4 weeks of enrollment
•Patients who are pregnant or breast-feeding
•History of prior malignancy other than ovarian cancer within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
•History of central nervous system metastases or carcinomatous meningitis
•Major surgery within 4 weeks of enrollment

Locations (5)

Scripps Health Center

La Jolla, California, United States

USC Women's and Children's Hospital

Los Angeles, California, United States

University of California San Francisco

San Francisco, California, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Roswell Park Cancer Center

Buffalo, New York, United States

Key Dates

Start Date

July 1, 2002

Last Updated

June 24, 2005

Enrollment

Estimated participants

Conditions

Ovarian Neoplasms

Interventions

intravenous T900607-sodium

DRUG

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

RECRUITINGPHASE1/PHASE2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695

Solid Tumor, AdultColorectal Cancer+18 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2005Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.

Inclusion Criteria

Exclusion Criteria

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Establishment of a Tumor Bank for Tissue Samples

Institut Paoli Calmettes Ovarian Cancer Database